Press Release | Biotechs Dynamic42 and Biopredic join for strategic Marketing agreement
New partnership to promote pioneering in vitro systems in drug development
Jena/Saint-Grégoire (FR), 25.01.2024 – The innovative organ-on-chip specialist Dynamic42 GmbH and Biopredic, manufacturer of assay systems for research, announce a strategic Marketing agreement. The joint partnership aims to advance the development of in vitro assay systems by using human-relevant models in the early phase of drug development.
The collaboration combines Dynamic42’s extensive know-how in the development of miniaturized human organ models (so-called organ-on-chip models) for drug testing using HepaRG™, the unique human hepatic cell model produced by Biopredic.
Dynamic42 uses the HepaRG™ model as an adequate surrogate to human primary hepatocytes (the “gold standard”) in their liver models for research purposes. Those liver models serve a critical aspect in drug development as they help to assess potential adverse effects of drugs on the liver, a vital organ responsible for metabolization and detoxification in the body. The liver model developed by Dynamic42 enables “bloodstream-like” intravenous drug application and detection of drug-induced liver injury.
Dynamic42 and Biopredic will work together to develop new applications based on Biopredic assay systems and Dynamic42 technologies. Joint Marketing activities are planned, including conference participation, joint presentations, and webinars.
“The strategic partnership with Biopredic marks an important milestone for Dynamic42. The integration of Biopredic cells with our organ models opens new opportunities for researchers and demonstrates our shared commitment to advancing methods in drug development,” says Dr. Knut Rennert, CEO of Dynamic42. “By combining our technologies, we will improve the quality and robustness of human organ model applications,” Dr. Rennert added.
“The combination of Biopredic assay models with Dynamic42 3D Microphysiological technologies would be very promising to upgrade the in vitro systems and offer fit-for-purpose tools for multiple applications. This vision fits into the Biopredic strategy of developing new recombinant HepaRG™ models and other unique hepatic systems along with original probes to screen the hepatic functions,” says Dr. El Azzi at Biopredic.
About Dynamic42
Dynamic42 GmbH was founded in 2018 and is a spin-off from the Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) of the University Hospital Jena. Dynamic42 markets and develops human organ-on-chip models/ microphysiological systems with integrated immune system components for research and testing of pharmaceutical products, novel therapies such as nanoparticles, chemical and food additives.
About Biopredic
Biopredic International is a French biotechnology company, subsidiary of Wepredic group, specializing in the design and manufacture of assay systems from human and animal biological materials for development and testing of drugs, cosmetics, and chemicals. Biopredic’s mission is to empower industrial and academic researchers with the tools they need to make a difference in the world of biomedicine with a primary focus on liver assay systems and human skin and blood samples: Biopredic, the exclusive producer of HepaRG™ cells, has been offering for 20 years now this relevant and robust model, widely considered as a surrogate of primary human hepatocytes.
Media Contact:
Dr. Juliane Fischer
PR Management
Dynamic 42 GmbH
Winzerlaer Straße 2
07745 Jena
Phone +49 3641 508101
Read more News:
Mari Kakihara joins Dynamic42 to support Finance and Controlling
We are excited to announce that Japhette Kembou-Ringert has joined us recently to support Finance and Controlling.
Press Release | The Dynamic42 3D intestinal chip model takes research of fungal infections to a new level
Dynamic42 GmbH has developed an intestine-on-chip candidiasis model that allows for the quantification of the infection process.
Dr. Japhette Kembou-Ringert joins Dynamic42 as Senior Scientist
We are excited to announce that Japhette Kembou-Ringert has joined us at the beginning of this year to support our lab team.